Efficacy and Safety of Multidisciplinary Sandwich Regimen in AQP4-IgG+ NMOSD With Preconception B-Cell Depletion During Perigravidity.
8 affiliations
- 1Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- 2Department of Obstetrics, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- 3Department of Neurology, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
- 4Department of Neurology, Neuromedicine Center, the University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
- 5Big Data and Artificial Intelligence Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- 6Department of Pharmacy, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- 7Center for Reproductive Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- 8Children Medical Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Abstract
Background
Neuromyelitis optica spectrum disorder (NMOSD) predominantly affects women of childbearing age, accompanied by markedly elevated relapse risks during pregnancy and postpartum periods, bringing great challenges to perigravid management. At present, there is no standardized gestational therapeutic regimen for NMOSD worldwide, and data on perigravid application of B-cell depleting agents including rituximab and inebilizumab remain limited. For patients exposed to B-cell depleting agents before conception, balancing disease control and fetal safety is an urgent clinical problem to be solved.Objective
This multicenter prospective cohort study aimed to evaluate the efficacy and safety of a three-stage multidisciplinary "sandwich" management regimen in AQP4-IgG-positive pregnant women with NMOSD exposed to B-cell depleting agents before conception. Maternal disease activity, pregnancy outcomes, neonatal conditions, and offspring growth and developmental characteristics within the first year of life were analyzed.Methods
A total of 8 AQP4-IgG-positive pregnant women with NMOSD who received B-cell depleting agents within 9 months prior to conception were enrolled from multiple centers between January 2022 and October 2024, including 3 patients treated with inebilizumab and 5 patients treated with rituximab. All subjects received a unified three-stage intervention: B-cell depleting agents were discontinued upon confirmed pregnancy; low-dose azathioprine combined with low-dose glucocorticoids was administered during gestation; B-cell depleting agents were reinitiated at 2 weeks postpartum. Multidisciplinary teams consisting of neurology, obstetrics, clinical pharmacy, and neonatology departments conducted full-cycle monitoring and follow-up. Primary observation indicators included maternal relapse events, Expanded Disability Status Scale (EDSS) scores, B-cell counts, gestational complications, gestational age at delivery, neonatal physical indicators, Apgar scores, congenital malformations, as well as offspring growth and neurodevelopment and vaccination safety from birth to 1 year of age.Results
All subjects achieved term live births without severe obstetric complications. Seven patients remained relapse-free throughout pregnancy and postpartum period with stable or improved EDSS scores; one patient discontinued all medications during gestation and suffered a relapse at 1 month postpartum. Neonatal physical indicators and Apgar scores were generally normal, one neonate presented mild hypospadias and two developed transient neonatal abnormalities; neonatal B-cell counts at birth and 1 month of age were within normal ranges. One-year follow-up showed normal physical and neurodevelopment in all offspring with safe vaccination procedures.Conclusions
For AQP4-IgG-positive pregnant women with NMOSD exposed to B-cell depleting agents before conception, the multidisciplinary "sandwich" regimen featuring B-cell depletion before conception and postpartum plus gestational bridging therapy with low-dose azathioprine combined with glucocorticoids is safe and effective, reduces disease relapse risk and yields favorable overall maternal and fetal outcomes. This regimen may serve as a promising perigravid management strategy that warrants further validation in larger cohorts.
Related
- Metabolic engineering of Salmonella enterica for coupled kynurenine sensing and depletion enhances antitumor efficacy
- LLM-assisted multidisciplinary decision-making in lung cancer: efficacy of Gemini-2.5-Pro and GPT-5 in a real-world MDT setting.
- ABCD-Trial: study protocol for a randomized, double-blind, placebo-controlled study in patients with Amyotrophic lateral sclerosis for the evaluation of efficacy and safety of B-Cell Depletion with rituximab (ABCD).
- Association of preconception and pregnancy dietary zinc and selenium intake with preeclampsia risk: results from a large birth cohort study
- Associations of Objective Functional and Subjective Health Literacy with Reproductive Health Knowledge and Preconception Preparedness Among Pregnant Women in Hungary
BibTeX
@article{xiao2026efficacy,
title = {{Efficacy and Safety of Multidisciplinary Sandwich Regimen in AQP4-IgG+ NMOSD With Preconception B-Cell Depletion During Perigravidity.}},
author = {Li Xiao and Gengxin Lu and Qian Gao and Feiyan Wan and Zhenze Lu and Wei Qiu and Chengfang Xu and Yaxin Lu and Lejia Xu and Tingting Xia and Jiajing Chao and Yu Fu and Zhuanggui Chen and Rui Li and Yanyu Chang and Yuge Wang and Bing Qin and Yaqing Shu},
journal = {CNS neuroscience \& therapeutics},
year = {2026},
month = oct,
doi = {10.1002/cns.71222},
url = {https://europepmc.org/article/MED/42924580},
note = {CC BY},
}
RIS
TY - JOUR
TI - Efficacy and Safety of Multidisciplinary Sandwich Regimen in AQP4-IgG+ NMOSD With Preconception B-Cell Depletion During Perigravidity.
AU - Li Xiao
AU - Gengxin Lu
AU - Qian Gao
AU - Feiyan Wan
AU - Zhenze Lu
AU - Wei Qiu
AU - Chengfang Xu
AU - Yaxin Lu
AU - Lejia Xu
AU - Tingting Xia
AU - Jiajing Chao
AU - Yu Fu
AU - Zhuanggui Chen
AU - Rui Li
AU - Yanyu Chang
AU - Yuge Wang
AU - Bing Qin
AU - Yaqing Shu
PY - 2026
DA - 2026/10/01
JO - CNS neuroscience & therapeutics
DO - 10.1002/cns.71222
UR - https://europepmc.org/article/MED/42924580
AB - Background Neuromyelitis optica spectrum disorder (NMOSD) predominantly affects women of childbearing age, accompanied by markedly elevated relapse risks during pregnancy and postpartum periods, bringing great challenges to perigravid management. At present, there is no standardized gestational therapeutic regimen for NMOSD worldwide, and data on perigravid application of B-cell depleting agents including rituximab and inebilizumab remain limited. For patients exposed to B-cell depleting agents before conception, balancing disease control and fetal safety is an urgent clinical problem to be solved.Objective This multicenter prospective cohort study aimed to evaluate the efficacy and safety of a three-stage multidisciplinary "sandwich" management regimen in AQP4-IgG-positive pregnant women with NMOSD exposed to B-cell depleting agents before conception. Maternal disease activity, pregnancy outcomes, neonatal conditions, and offspring growth and developmental characteristics within the first year of life were analyzed.Methods A total of 8 AQP4-IgG-positive pregnant women with NMOSD who received B-cell depleting agents within 9 months prior to conception were enrolled from multiple centers between January 2022 and October 2024, including 3 patients treated with inebilizumab and 5 patients treated with rituximab. All subjects received a unified three-stage intervention: B-cell depleting agents were discontinued upon confirmed pregnancy; low-dose azathioprine combined with low-dose glucocorticoids was administered during gestation; B-cell depleting agents were reinitiated at 2 weeks postpartum. Multidisciplinary teams consisting of neurology, obstetrics, clinical pharmacy, and neonatology departments conducted full-cycle monitoring and follow-up. Primary observation indicators included maternal relapse events, Expanded Disability Status Scale (EDSS) scores, B-cell counts, gestational complications, gestational age at delivery, neonatal physical indicators, Apgar scores, congenital malformations, as well as offspring growth and neurodevelopment and vaccination safety from birth to 1 year of age.Results All subjects achieved term live births without severe obstetric complications. Seven patients remained relapse-free throughout pregnancy and postpartum period with stable or improved EDSS scores; one patient discontinued all medications during gestation and suffered a relapse at 1 month postpartum. Neonatal physical indicators and Apgar scores were generally normal, one neonate presented mild hypospadias and two developed transient neonatal abnormalities; neonatal B-cell counts at birth and 1 month of age were within normal ranges. One-year follow-up showed normal physical and neurodevelopment in all offspring with safe vaccination procedures.Conclusions For AQP4-IgG-positive pregnant women with NMOSD exposed to B-cell depleting agents before conception, the multidisciplinary "sandwich" regimen featuring B-cell depletion before conception and postpartum plus gestational bridging therapy with low-dose azathioprine combined with glucocorticoids is safe and effective, reduces disease relapse risk and yields favorable overall maternal and fetal outcomes. This regimen may serve as a promising perigravid management strategy that warrants further validation in larger cohorts.
SN - 1755-5930
SN - 1755-5949
ER -